BK0218 Specialty Pharmaceuticals
- 1963.054
- +48.621+2.54%
Jiangsu Wuzhong (600200): Losses have narrowed in 23 years and recently, Tongyan acupuncture has been on the market
Core view 24Q1: The steady increase in revenue in the pharmaceutical business helped increase revenue by 15%, and the performance was under pressure from investment in the medical and aesthetic business. The company's pharmaceutical business contributed the main revenue in '23, and some pharmaceutical products lost revenue due to withdrawal from medical insurance and national collection
Zhendong Pharmaceutical (300158.SZ) has repurchased 2.16% of its shares at a total cost of 103 million yuan
Zhendong Pharmaceutical (300158.SZ) announced that the company's repurchase has been completed. As of April 30, 2024, the company had repurchased a total of 22.174,900 shares of the company's shares, accounting for 2.16% of the company's total share capital, and the total transaction amount was 103 million yuan (excluding transaction fees).
Express News | Tonghua Dongbao: Phase IIa clinical trial of gout dual-target inhibitors (THDBH151 tablets) completed the first patient administration.
Express News | Rheinbio: Completed the first phase of research goals for the synthesis of rohan guosin
Fosun Pharmaceutical (02196.HK) has yet to repurchase shares
Gelonghui, May 6, 丨 Fosun Pharmaceutical (02196.HK) issued an announcement. From March 26, 2024 (that is, the date the board of directors reviewed and approved the repurchase plan) to April 30, 2024, the company has not yet repurchased shares under the repurchase plan.
China Grants Marketing Authorization to Sunflower Pharma's Electrolyte Powder for Constipation
China's medical products administrator granted marketing authorization to Sunflower Pharmaceutical (SHE:002737) subsidiary Harbin Sunflower Pharmaceutical's compound polyethylene glycol electrolyte po
Hengrui Pharmaceutical (600276.SH): cumulative repurchase of 0.22% of shares
Gelonghui, May 6, 丨 Hengrui Pharmaceutical (600276.SH) announced that as of April 30, 2024, the company had repurchased a total of 14,351,878 shares through centralized bidding transactions, accounting for 0.22% of the company's total share capital. The highest transaction price was 47.01 yuan/share, the lowest price was 41.09 yuan/share, and the total amount paid was 634,665,849.66 yuan (excluding transaction fees).
Express News | Fosun Pharmaceuticals: The holding subsidiary was approved for clinical trials by the US FDA
Jiuzhou Pharmaceutical (603456.SH): cumulative share repurchases of 3.895,300 shares
Gelonghui, May 6, 丨 Jiuzhou Pharmaceutical (603456.SH) announced that as of April 30, 2024, the company had repurchased a total of 3,895,300 shares through centralized bidding transactions. The repurchased shares accounted for 0.43% of the company's total share capital. The highest transaction price was 22.18 yuan/share, the lowest price was 15.11 yuan/share, and the total amount paid was 69,993,558.10 yuan (excluding transaction fees).
Express News | Shanghai Pharmaceuticals: Levosimendan injection approved for production
Kehua Biotech (002022.SZ) has spent 72.613,900 yuan to buy back 1.74% of shares
Kehua Biotech (002022.SZ) issued an announcement. As of April 30, 2024, the company has approved a total of shares...
Express News | Shuangcheng Pharmaceutical: Octreotide acetate injection ANDA obtained marketing approval from the US FDA
Zhongyuan Xiehe (600645.SH): A total of 1.65% of the company's shares have been repurchased
Gelonghui, May 6, 丨 Zhongyuan Xiehe (600645.SH) announced that as of April 30, 2024, the company had repurchased a total of 7,707,940 shares, accounting for 1.65% of the company's total share capital. The highest purchase price was 17.95 yuan/share, the lowest price was 15.11 yuan/share, and the total amount paid was 125,389,095.38 yuan (not including transaction fees).
Northeast Pharmaceutical's Unit Gets Nod to Produce Azithromycin for Injection
Northeast Pharmaceutical Group's (SHE:000597) unit, Dongyao Group Shenyang Shide Pharmaceutical, received a drug registration certificate from China's National Medical Products Administration for the
We Think You Should Be Aware Of Some Concerning Factors In China Meheco Group's (SHSE:600056) Earnings
China Meheco Group Co., Ltd.'s (SHSE:600056) robust recent earnings didn't do much to move the stock. We believe that shareholders have noticed some concerning factors beyond the statutory profit num
Sinopharm is consistent (000028): Fee control effects are gradually showing optimism about improving profitability throughout the year
Core view On April 25, the company released the first quarter results report of 2024. In 24Q1, it achieved operating income of 19.090 billion yuan, an increase of 2.16% over the previous year, and achieved net profit of 389 million yuan to mother, an increase of 389 million yuan over the previous year
The top-level file will be released soon! The concept of synthetic biology has risen to prominence, and the pace of industrial development has accelerated
Trillion racetrack
Is Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Recent Stock Performance Tethered To Its Strong Fundamentals?
Zhejiang Huahai Pharmaceutical (SHSE:600521) has had a great run on the share market with its stock up by a significant 47% over the last three months. Since the market usually pay for a company's l
Why Investors Shouldn't Be Surprised By Guangxi Wuzhou Zhongheng Group Co.,Ltd's (SHSE:600252) Low P/S
With a price-to-sales (or "P/S") ratio of 2.6x Guangxi Wuzhou Zhongheng Group Co.,Ltd (SHSE:600252) may be sending bullish signals at the moment, given that almost half of all the Pharmaceuticals comp
Express News | Today, 17 companies lifted the ban on restricted shares, and the market value of Crystal Integration was lifted to exceed 10 billion dollars